| Literature DB >> 26217728 |
Daymi Camejo1, Ana Ortiz-Espín1, Juan J Lázaro2, María C Romero-Puertas2, Alfonso Lázaro-Payo2, Francisca Sevilla1, Ana Jiménez1.
Abstract
S-nitrosylation is emerging as a key post-translational protein modification for the transduction of NO as a signaling molecule in plants. This data article supports the research article entitled "Functional and structural changes in plant mitochondrial PrxII F caused by NO" [1]. To identify the Cys residues of the recombinant PrxII F modified after the treatment with S-nitrosylating agents we performed the LC ESI-QTOF tandem MS and MALDI peptide mass fingerprinting analysis. Change in A 650 nm was monitored to estimate the thermal aggregation of citrate synthase in the presence S-nitrosylated PrxII F. The effect of the temperature on the oligomerization pattern and aggregation of PrxII F was analysed by SDS-PAGE and changes in absorbance at 650 nm, respectively.Entities:
Keywords: Citrate synthase; Oligomerization; PrxII F; S-nitrosylation
Year: 2015 PMID: 26217728 PMCID: PMC4510073 DOI: 10.1016/j.dib.2015.02.009
Source DB: PubMed Journal: Data Brief ISSN: 2352-3409
Fig. 1Electrophoretic mobility on SDS-PAGE visualized by silver staining of the recombinant PsPrxII F treated with 5 mM GSNO (PrxII F GSNO) and 50 mM DTT (PrxII F-SH) (A). Peptide analysis were carried out by nano LC ESI–QTOF tandem MS analysis using an Eksigent 1D-nanoHPLC coupled to a 5600 Triple TOF QTOF mass spectrometer (ABSciex, Framinghan, MA, USA). Peptides identified as susceptible of modification (nitrosyl group) in the monomeric form in the Cys 84, GVDSVIC84VAINDPYTVNAWAEK (B); in the monomeric form on the Cys 59 KVVIFGLPGAYTGVC59SSK (C), and dimeric form on the Cys 84 GVDSVIC84VAINDPYTVNAWAEK (D).
Fig. 2Electrophoretic mobility on SDS-PAGE visualized by silver staining of the recombinant PsPrxII F treated with 5 mM GSNO (PrxII F GSNO) and 50 mM DTT (PrxII F-SH). The table shows the m/z of the Cys 59 identified as target of modification by HPDP-biotin. MS and MS/MS spectra were obtained by UltrafleXtreme MALDI-TOF/TOF mass spectrometer (Bruker-Daltonics) in auto-mode using Flex Control v3.4 (Bruker-Daltonics).
Fig. 3Chaperone activity estimated from the ability of PsPrxII F to inhibit the thermal aggregation of citrate synthase (CS). PrxII F treated with 5 mM GSNO (A) and 250 µM SNP (B) was incubated with CS at a molar ratio (0.5:1, 1:1, 2:1). Samples were separated into pellet and soluble fractions and equal volumes were analysed by SDS-PAGE and visualized by silver staining. Thermal aggregation is evident from the amount of CS present in the pellet fraction after of incubated with GSNO (C) and SNP (D) at the molar ratios (0.5:1, 1:1, 2:1). The numbers represent the intensity of the bands quantified on an image analyser (Gen Tools, Syngene Frederick, MD). The significance of differences between means values was determined by one-way analysis of variance. Duncan׳s multiple range test was used to compare the means when necessary. All error bars represent standard error (SE) of the mean. The asterisk above the bars indicates significant difference (P<0.01).
Fig. 4Electrophoretic mobility on SDS-PAGE visualized by Coomasie staining of the recombinant PsPrxII F treated with 50 mM DTT (PrxII F-SH), 5 mM GSNO (PrxII F GSNO) and 250 μM SNP (PrxII F SNP) incubated at 25 °C and 45 °C during 30 min (A). Light scattering at 650 nm of PrxII F treated with DTT, GSNO and SNP incubated at 45 °C during 1800 s (B).
| Subject area | Biology |
|---|---|
| More specific subject area | |
| Type of data | |
| How data was acquired | |
| Data format | |
| Experimental factors | The recombinant pea mitochondrial PrxII F (PsPrxII F) was incubated with S-nitrosylating agents 5 mM GSNO (S-nitrosoglutathione) and the NO donor 250 μM SNP (sodium nitroprusside dehydrate) for 30 min at 30 °C. |
| Experimental features | The thermal aggregation of citrate synthase was evaluated by light scattering at 650 nm during 1800 s at 45 °C. |
| Data source location | All the analysis were performed in Spain. MS analysis was carried out in the National Biotechnology Center (CSIC, Spain). |
| Data accessibility | The data are provided in this article. |